-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In 2022, the countdown to the adjustment of the medical insurance catalogue has begun, and the 14 exclusive proprietary Chinese medicines that have passed the formal review are expected to join a new round of fierce battle, and the sales of exclusive medical insurance products have also attracted market attention
.
According to data from Intranet, there are more than 300 exclusive proprietary Chinese medicines in the 2021 edition of the national medical insurance catalogue with terminal sales of more than 100 million yuan in China's public medical institutions last year, and Tasly's compound salvia drop pills won the first
place with sales of more than 3.
2 billion yuan.
From the perspective of the number of products, Buchang Pharmaceutical, Shanghai Pharmaceutical, and China Resources Pharmaceutical are leading, while Kangyuan Pharmaceutical, Yangtze River Pharmaceutical, and Lunan Pharmaceutical continue to explode, and the potential can be expected
。 Medical insurance exclusive proprietary Chinese medicine is super eye-catching! The most cardiovascular and cerebrovascular blockbuster products Statistics from Intranet show that in 2021, at the terminals of urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions), 327 exclusive proprietary Chinese medicines that have entered the 2021 edition of the national medical insurance catalogue have sold more than 100 million yuan, mainly distributed in 13 categories, of which more than 200 products maintained positive sales growth in the first half of 2022
.
Table 1: Medical insurance exclusive proprietary Chinese medicines with sales of more than 100 million yuan in 2021 Drugs for cardiovascular and cerebrovascular diseases, musculoskeletal diseases, digestive diseases, respiratory diseases and gynecology are the top 5 categories, and the total number of exclusive products with sales of more than 100 million yuan in 2021 accounts for more than 60%
of the total.
More than 1 billion exclusive products are concentrated in cardiovascular and cerebrovascular diseases, and respiratory diseases also account for 6.
Gynecological drugs, neurological disease drugs, dermatology drugs and other drugs in 2021 do not have exclusive products with sales of more than 1 billion, and these categories may become new competitive breakthroughs
.
The 2021 version of the national medical insurance catalogue has been implemented on January 1 this year, Intranet recently released the sales data of China's public medical institutions in the first half of 2022, from the sales growth in the first half of this year, dermatology drugs 5 exclusive products over 100 million have maintained a positive growth trend, except for tumor disease drugs, more than half of the other categories of products have positive growth
.
In the first half of 2022, there are 3 products that fell by more than 50%, including 1 drug for respiratory diseases, 1 for tumor diseases, and 1 for pediatrics
.
More than 1 billion list exposed, compound danshen drop pills firmly ranked first Table 2: Medical insurance exclusive proprietary Chinese medicine with terminal sales of more than 1 billion yuan in China's public medical institutions in 2021 Note: *Products with a limited scope of use Tasly Pharmaceutical Group's compound danshen pills are used for cardiovascular and cerebrovascular diseases, and the terminal sales of public medical institutions in China exceeded 3.
2 billion yuan in 2021, becoming the best-selling exclusive proprietary Chinese medicine
.
The latest data from Intranet shows that the product won a sales performance of 1.
5 billion yuan in the first half of 2022 and continued to rank first
.
The sales of 13 exclusive products in the first half of 2022 maintained a positive growth trend, and the growth rate of Suhuang cough capsules, uroxin clear granules (sugar-free type), pediatric soybean clear heat granules, lung cough mixture, Yindanxin Brain Tong soft capsules and blood treasure mixture reached double-digit
growth.
Figure 1: Exclusive proprietary Chinese medicine with sales growth rate of more than 10% in the first half of 2022 (10,000 yuan) Yangtze River Pharmaceutical's Suhuang cough capsules are used for respiratory diseases, which is a famous prescription of Chinese medicine master Chao Enxiang, specializing in the treatment of wind and cough
.
In 2021, the sales of the product exceeded 1.
7 billion yuan in the terminal of public medical institutions in China, with a growth rate of 27%, and the latest data show that the sales of the product in the first half of 2022 are close to 990 million yuan, and the growth rate again reaches more than
20%.
Kangchen Pharmaceutical's uric toxin granules (sugar-free type) is used for urinary system diseases and is the first modern proprietary Chinese medicine
for the treatment of chronic renal failure in China.
Since its launch, the product has maintained a positive growth trend in China's public medical institutions, breaking through the 1 billion yuan mark in 2017, rising to more than 1.
6 billion yuan in 2021, with a growth rate of 13.
7%, and has achieved sales of 900 million yuan in the first half of 2022, with a growth rate of 19.
5%.
Jichuan Pharmaceutical's Pediatric Heat Granules are derived from the ancient recipe "Yinqiao Scatter", which is used in children with wind, heat and cold, and cold stagnation, and is the only exclusive product
of more than 1 billion yuan in the current pediatric drug market.
In 2021, the sales of this product exceeded 1.
4 billion yuan in China's public medical institutions, with a growth rate of 47.
8%, and the sales in the first half of 2022 exceeded 900 million yuan, with a growth rate of 14.
9%.
Guizhou Jianxing Pharmaceutical's pulmonary cough mixture is a seedling medicine for respiratory diseases
.
In 2021, the sales of this product exceeded 1.
2 billion yuan in the terminal of public medical institutions in China, with a growth rate of 30.
3%, and the sales in the first half of 2022 exceeded 600 million yuan, with a growth rate of 16.
3%.
Guizhou Bailing's Yindanxin Brain Soft Capsule is also a seedling medicine, which is used for cardiovascular and cerebrovascular diseases
.
The sales of the product successfully exceeded 1 billion yuan in 2020 in China's public medical institution terminals, rose to more than 1.
2 billion yuan in 2021, and exceeded 600 million yuan in the first half of 2022, with a growth rate of 15.
6%.
Tsinghua Deren Xi'an Xingfu Pharmaceutical's blood constitution is a qi and blood replenishing drug, which has maintained a positive growth trend since its listing, and the terminal sales of public medical institutions in China exceeded 1 billion yuan for the first time in 2021, and at the same time became the only exclusive product
of more than 1 billion yuan for qi and blood replenishment.
In the first half of 2022, the sales of this product have exceeded 500 million yuan, and the growth rate continues to remain in double digits
.
Buchang Pharmaceutical's Danhong injection is also very noteworthy, the product was required to be "limited to secondary and above medical institutions" in the 2017 version of the national medical insurance catalogue, and then retained this description
in the 2019 edition of the national medical insurance catalogue and the 2020 version of the negotiation catalogue.
The 2021 version of the medical insurance negotiation catalogue deleted this description, and the growth rate of the product in China's public medical institutions in the first half of 2022 stopped falling and rebounded by 8%, with sales exceeding 700 million yuan
.
TOP10 enterprises are fiercely fighting, Kangyuan maintains a rising trend, Yangtze River and Lunan attack Figure 2: Ranking of exclusive proprietary Chinese medicine enterprises with sales of more than 100 million in 2021 Note: According to group statistics, the number of products is ranked in the same ranking Buchang Pharmaceutical's exclusive proprietary Chinese medicines with sales of more than 100 million yuan in 2021 are concentrated in 7 categories, involving cardiovascular and cerebrovascular diseases, digestive system diseases, ENT drugs, nervous system diseases, urinary system diseases, Medication for musculoskeletal system diseases and gynecological medication
.
There are 3 products with more than 1 billion, including Brain Heart Capsules, Steady Heart Granules and Danhong Injection; In addition to Danhong injection, sales of prostalactone capsules, ginkgo honey ring oral solution, liver refreshing granules and Xiangju capsules maintained positive growth
in the first half of 2022.
Shanghai Pharmaceutical's exclusive proprietary Chinese medicines, with sales of more than 100 million yuan in 2021, are concentrated in four categories, involving drugs for cardiovascular and cerebrovascular diseases, oncology diseases, digestive diseases, and musculoskeletal diseases
.
The sales of musk baoxin pills in 2021 exceeded 2 billion yuan, in addition to 8 products in the first half of 2022 sales maintained positive growth, of which gastric rejuvenation capsules sales have soared since 2020, sales exceeded 200 million yuan in 2021, and have reached 210 million yuan in the first half of 2022, with a growth rate of nearly 240%.
Kangyuan Pharmaceutical's exclusive proprietary Chinese medicines with sales of more than 100 million yuan in 2021 are concentrated in 6 categories, involving cardiovascular and cerebrovascular diseases, musculoskeletal system diseases, gynecological drugs, neurological diseases, respiratory diseases and pediatrics
.
The sales of the 9 major products in the first half of 2022 all maintained positive growth, among which Jinzhen oral liquid, lumbar paralysis capsules, Tianshu capsules, loose knot analgesic capsules, and Tong plug pulse tablets grew by double digits
.
Yangtze River Pharmaceutical's exclusive proprietary Chinese medicines with sales of more than 100 million yuan in 2021 are concentrated in five categories, involving drugs for digestive diseases, drugs for ENT medicines, drugs for neurological diseases, drugs for respiratory diseases and pediatric drugs
.
The sales of Suhuang cough capsules and Lanqin oral liquid both exceeded 1 billion yuan in 2021, and both had positive growth in the first half of 2022; Since 2020, the sales of Scattered Wind Tongjiao Di Pill have soared, and in 2021, it has become a new exclusive proprietary Chinese medicine of over 100 million yuan, with a growth rate of 336%, and the sales in the first half of 2022 have exceeded 80 million yuan, with a growth rate of 122%.
Lunan Pharmaceutical's exclusive proprietary Chinese medicines with sales of more than 100 million yuan in 2021 are concentrated in four categories, involving cardiovascular and cerebrovascular diseases, pediatric drugs, digestive system diseases and ENT drugs
.
Since entering the national medical insurance directory in 2017, the company's sales of Sichuan Leech Tongluo capsules have soared rapidly, and in 2021, they will become the new exclusive proprietary Chinese medicine of more than 100 million yuan in the terminal of China's public medical institutions, with a growth rate of up to 113%, and the product has won more than 80 million yuan in sales in the first half of 2022, with a growth rate of more than 68%.
。 Conclusion The new version of the Chinese medicine registration management measures has been implemented since July 2020, and the first new Chinese medicine class 1.
1 drug Yinqiao Qingqiao Qingqiao Tablet was approved in November 2021, and it is impossible to participate in the adjustment of the 2021 version of the medical insurance catalogue (the deadline for approval is June 30 of that year), so whether the 2022 version of the medical insurance catalogue will include Class 1 new drugs of Chinese medicines has also become one of
the hot topics in the market.
Of the 14 exclusive proprietary Chinese medicines that have passed the formal examination, 7 are Class 1.
1 new drugs, Yili Group, Yiling Pharmaceutical, Tasly, Jianmin Pharmaceutical, Shandong Phoenix Pharmaceutical, Fangsheng Pharmaceutical and Kangyuan Pharmaceutical, who can be the winner, usWe'll see
.
Source: Intranet database Note: Intranet "Terminal Competition Pattern of China's Public Medical Institutions", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). 
